Dyskinesia Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Teva Pharmaceutical, Neurocrine Biosciences, Inc, Sun Pharmaceutical, SteriMax Inc., Adamas Pharmaceuticals

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Dyskinesia pipeline constitutes 45+ key companies continuously working towards developing 45+ Dyskinesia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Dyskinesia Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Dyskinesia Market.

The Dyskinesia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Dyskinesia Pipeline Report: https://www.delveinsight.com/sample-request/dyskinesia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Dyskinesia treatment therapies with a considerable amount of success over the years.
• Dyskinesia companies working in the treatment market are PolyCore Therapeutics, Melior Pharmaceuticals, MapLight Therapeutics, Luye Pharma Group, Contera Pharma, Neurolixis, Celon Pharma, and others, are developing therapies for the Dyskinesia treatment
• Emerging Dyskinesia therapies in the different phases of clinical trials are- PCT-3012, Mesocarb, ML 007, LY 03015, JM-010, NLX 112, CPL 500036, and others are expected to have a significant impact on the Dyskinesia market in the coming years.
• In May 2022, At the American mental Association Annual Meeting in 2022, Neurocrine Biosciences presented updated INGREZZA (valbenazine) data on tardive dyskinesia improvement and stability of mental symptoms.
• In August 2021, Results of a post hoc analysis of a long-term, three-year open-label extension (OLE) study examining efficacy and safety endpoints for the use of AUSTEDO (Deutetrabenazine) tablets in younger (55 years old) and older (55 years old) patients with tardive dyskinesia (TD) were released by Teva Pharmaceuticals, a subsidiary of Teva Pharmaceutical Industries Ltd. in the United States.
• In April 2021, A randomized, double-blind, placebo-controlled, two-part study was started by Bukwang Pharmaceutical with the goal of determining the effectiveness and safety/tolerability of fixed dose combinations of JM-010 and its individual components in patients with Parkinson's disease who also had dyskinesia.

Dyskinesia Overview
A movement disorder called dyskinesia frequently manifests as uncontrollably shaking, ticing, or trembling. People who have Parkinson's disease frequently develop the condition as a result of drugs that overstimulate their dopamine receptors, increasing this neurotransmitter in the brain.

Get a Free Sample PDF Report to know more about Dyskinesia Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/dyskinesia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Dyskinesia Drugs Under Different Phases of Clinical Development Include:
• PCT-3012: PolyCore Therapeutics
• Mesocarb: Melior Pharmaceuticals
• ML 007: MapLight Therapeutics
• LY 03015: Luye Pharma Group
• JM-010 : Contera Pharma
• NLX 112: Neurolixis
• CPL 500036: Celon Pharma

Dyskinesia Route of Administration
Dyskinesia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Dyskinesia Molecule Type
Dyskinesia Products have been categorized under various Molecule types, such as
• Oligonucleotide
• Peptide
• Small molecule

Dyskinesia Pipeline Therapeutics Assessment
• Dyskinesia Assessment by Product Type
• Dyskinesia By Stage and Product Type
• Dyskinesia Assessment by Route of Administration
• Dyskinesia By Stage and Route of Administration
• Dyskinesia Assessment by Molecule Type
• Dyskinesia by Stage and Molecule Type

DelveInsight's Dyskinesia Report covers around 45+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Dyskinesia product details are provided in the report. Download the Dyskinesia pipeline report to learn more about the emerging Dyskinesia therapies at:
https://www.delveinsight.com/sample-request/dyskinesia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Dyskinesia Therapeutics Market include:
Key companies developing therapies for Dyskinesia are - Teva Pharmaceutical, Neurocrine Biosciences, Inc, Sun Pharmaceutical, SteriMax Inc., Adamas Pharmaceuticals, Inc, Sanis, AbbVie Inc, and others.

Dyskinesia Pipeline Analysis:
The Dyskinesia pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Dyskinesia with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Dyskinesia Treatment.
• Dyskinesia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Dyskinesia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Dyskinesia market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Dyskinesia drugs and therapies-
https://www.delveinsight.com/sample-request/dyskinesia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Dyskinesia Pipeline Market Drivers
• Increase in prevalence of Dyskinesia, increase in the demand for disease specific novel treatment are some of the important factors that are fueling the Dyskinesia Market.

Dyskinesia Pipeline Market Barriers
• However, lack of understanding of the pharmacology of Dyskinesia, side-effects associated with drugs and other factors are creating obstacles in the Dyskinesia Market growth.

Scope of Dyskinesia Pipeline Drug Insight
• Coverage: Global
• Key Dyskinesia Companies: PolyCore Therapeutics, Melior Pharmaceuticals, MapLight Therapeutics, Luye Pharma Group, Contera Pharma, Neurolixis, Celon Pharma, and others
• Key Dyskinesia Therapies: PCT-3012, Mesocarb, ML 007, LY 03015, JM-010, NLX 112, CPL 500036, and others
• Dyskinesia Therapeutic Assessment: Dyskinesia current marketed and Dyskinesia emerging therapies
• Dyskinesia Market Dynamics: Dyskinesia market drivers and Dyskinesia market barriers

Request for Sample PDF Report for Dyskinesia Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/dyskinesia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Dyskinesia Report Introduction
2. Dyskinesia Executive Summary
3. Dyskinesia Overview
4. Dyskinesia- Analytical Perspective In-depth Commercial Assessment
5. Dyskinesia Pipeline Therapeutics
6. Dyskinesia Late Stage Products (Phase II/III)
7. Dyskinesia Mid Stage Products (Phase II)
8. Dyskinesia Early Stage Products (Phase I)
9. Dyskinesia Preclinical Stage Products
10. Dyskinesia Therapeutics Assessment
11. Dyskinesia Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Dyskinesia Key Companies
14. Dyskinesia Key Products
15. Dyskinesia Unmet Needs
16 . Dyskinesia Market Drivers and Barriers
17. Dyskinesia Future Perspectives and Conclusion
18. Dyskinesia Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Dyskinesia Market https://www.delveinsight.com/report-store/dyskinesia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Dyskinesia Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Dyskinesia Epidemiology https://www.delveinsight.com/report-store/dyskinesia-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Dyskinesia Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:
Oncology Drugs Market
https://www.delveinsight.com/report-store/oncology-drugs-market
Oncology Drugs Market By Therapy Type (Chemotherapy, Hormonal Therapy, Targeted Therapy [Gene Therapy And Immunotherapy], And Others), By Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Blood Cancers, And Others), By End User (Hospitals, Specialty Clinics, And Others), and by geography is estimated to grow at a healthy CAGR forecast till 2028 due to rising prevalence of various cancers such as lung and breast cancers and growing demand for targeted therapies for cancer treatment.

Biologics Market
https://www.delveinsight.com/report-store/biologics-market
Biologics Market By Product Type (Cell-Based Biologics, Gene-Based Biologics, Monoclonal Antibodies, Vaccines, Recombinant Protiens, And Others), By Application (Oncology, Immunology, Infectious Diseases, Neurological Diseases, And Others), By Manufacturing Type (In-House And Outsourced), and by geography is expected to grow at a steady CAGR forecast till 2028 owing to rising prevalence of autoimmune disorders such as rheumatoid arthiritis and genetic disorders.

Biosimilar Market
https://www.delveinsight.com/report-store/biosimilars-market
Biosimilars Market By Product Class (Monoclonal Antibodies, Recombinant Hormone/Proteins, Anti-Inflammatory Agents, Immunomodulators, And Others), By Manufacturing Type (In-House And Outsourced/Contract), By Application (Autoimmune Diseases, Blood Disorders, Oncology, Infectious Diseases, And Others), by geography, is projected to expand at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders such as autoimmune disorders, cancers, among others and increasing demand for biosimilar drugs owing to their cost-effectiveness.

Cancer Immunotherapy Market
https://www.delveinsight.com/report-store/cancer-immunotherapy-market
Cancer Immunotherapy Market By Type (Monoclonal Antibodies, Immunomodulators, Cancer Vaccines, Checkpoint Inhibitors, And Others), By Indication (Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, And Others), By End-User (Hospitals And Clinics, Specialty Centers, And Others), and by geography is expected to rise at a significant CAGR forecast till 2027 owing to the accelerating prevalence of cancers and surging healthcare expenditure across the globe

Companion Diagnostics Market
https://www.delveinsight.com/report-store/companion-diagnostics-market
Companion Diagnostics Market By Type (Product [Assays, Kits & Reagents And Instruments], and Services), Technology (Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), and Others), Indication (Lung Cancer, Breast Cancer, Colorectal Cancer, and Others), End-User (Hospitals, Diagnostic Labs, and Others), and Geography is expected to grow at a noteworthy CAGR till 2028 owing to the increase in the cancer burden across the globe and the growing focus on personalized medicines.

Telemedicine Service Market
https://www.delveinsight.com/report-store/telemedicine-service-market
Telemedicine Service Market By Service Type (Tele Consulting And Tele Monitoring), By Application (Telepathology, Telecardiology, Teleradiology, Teledermatology, Telepsychiatry, Other Services), By End-User (Healthcare Facilities And Homecare), by geography, is projected to grow at a significant CAGR forecast till 2028 owing to the sudden outbreak of covid-19 pandemic and shifting focus for reducing the burden of healthcare cost.

DNA Sequencing Market
https://www.delveinsight.com/report-store/dna-sequencing-market
DNA Sequencing Market By Products & Services (Instruments, Consumbales, And Services), By Technology (Sanger Sequencing, Next-Generation Sequencing, And Long-Read Sequencing), By Application (Disease Diagnosis, Precision Medicine, And Research), By End User (Hospitals & Clinics, Diagnostic Laboratories, Pharmaceutical Companies, And Academic Institutes), and by geography is estimated to grow at an appreciable CAGR forecast till 2028 owing to rising prevalence of genetic disorders and growing popularity of precision medicine.

Next Generation Sequencing Market
https://www.delveinsight.com/report-store/next-generation-sequencing-market
Next-Generation Sequencing Market By Product Type (Instruments, Reagents & Consumables And Services), By Sequencing Type (Whole-Genome Sequencing, Whole-Exome Sequencing, Rna Sequencing, Targeted Sequencing, De-Novo Sequencing, Others), By Application (Diagnostic, Drug Discovery, Agriculture & Animal Research, Others), By End-User (Pharmaceutical & Biotechnology Companies, Hospitals & Clinics, Academic & Research Institute), by geography, is expected to grow at a significant CAGR forecast till 2028 owing to the rising application of next-generation sequencing (NGS) technology in clinical diagnosis and advancement in NGS platforms.

Active Pharmaceutical Ingredient Market
https://www.delveinsight.com/report-store/active-pharmaceutical-ingredient-api-market
Active Pharmaceutical Ingredient (API) Market By Type (Innovative And Generic), By Manufacturer Type (Captive And Merchant), By Synthesis Type (Synthetic And Biotech), By Application (Oncology, Cardiology, Pulmonology, Neurology, Orthopedic, Opthalmology, And Others), by geography is estimated to register growth at remarkable CAGR forecast till 2027 owing to rising prevalence of various diseases such as diabetes and growing focus on drug development

Clinical Diagnostics Market
https://www.delveinsight.com/report-store/clinical-diagnostics-market
Clinical Diagnostics Market By Type (Products [Instruments, Kits & Reagents], Services), Test (Complete Blood Count (CBC), Metabolic Panel, Lipid Panel, Renal Panel, Liver Panel, Infectious Disease Testing, and Others), End-User (Hospitals, Pathology Labs, and Others), and Geography, is expected to expand at a significant CAGR till 2028 owing to the growing cases of various chronic diseases & infectious diseases across the globe and rise in the integration of technological advancements in the product portfolio.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.